Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 4/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.71 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.66 |
| ▸ | PI4KA | P42356 | 2/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.65 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.65 |
| ▸ | AHCY | P23526 | 7/20 | 0.63 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29459142 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADCY1PI4KA | |
| Hydrochloric Acid SCHEMBL9193028 | 0.98 | ADORA2A (0.97) | ADORA2AADORA1ADORA2BADCY1PI4KA | |
| SCHEMBL1635576 | 0.90 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADCY1PI4KA | |
| SCHEMBL11222112 | 0.89 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL19553487 | 0.89 | ADORA2A (0.91) | ADORA2AADORA1ADORA2BADCY1PI4KA | |
| SCHEMBL8467390 | 0.87 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BADCY1PI4KA | |
| SCHEMBL1871838 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL2638103 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL5033136 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11487766 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BADCY1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| CN-116854772-A | Analogue of endomorphin and adenine conjugated peptide with analgesic activity and synthesis method thereof | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| CN-113939599-A | Hybrid all-LNA oligonucleotides | 豪夫迈·罗氏有限公司 | 2022-01-14 | — | — | CN | claimed |
| WO-2020245377-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-10 | — | — | WO | claimed |
| EP-2682397-B1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES INC (US) | 2017-04-19 | — | — | EP | claimed |
| CN-106105477-A | A kind of quick pregermination method of Semen Maydis | 安徽省固镇县谷阳有机蔬菜专业合作社 | 2016-11-16 | — | — | CN | claimed |
| EP-1572095-B1 | BETA-L-2'-DEOXYNUCLEOSIDES FOR USE IN THE TREATMENT OF RESISTANT HBV STRAINS | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | claimed |
| US-20040018150-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | BECKER MARK W (US) | 2004-01-29 | — | — | US | claimed |
| US-20030219727-A1 | Prodrugs of phosphonate nucleotide analogues | BECKER MARK W (US) | 2003-11-27 | — | — | US | claimed |
| EP-1301519-A2 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES, INC. (US) | 2003-04-16 | — | — | EP | claimed |
| EP-1256585-A1 | Process fot preparing 9-(2-(diethylphosphonomethoxy)ethyl)-adenine | GILEAD SCIENCES, INC. (US) | 2002-11-13 | — | — | EP | claimed |
| US-6451340-B1 | CRYSTALLINE ADEFOVIR DIPIVOXIL | GILEAD SCIENCES, INC. | 2002-09-17 | — | — | US | claimed |
| US-20020119443-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES, INC. | 2002-08-29 | — | — | US | claimed |
| US-20020045599-A1 | Nucleotide analog compositions | GILEAD SCIENCES, INC. | 2002-04-18 | — | — | US | claimed |
| WO-2002008241-A2 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| EP-0996430-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999004774-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 1999-02-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040018150-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | PNP, PNPO, MTAP | ADORA2A 103/4885ADORA1 133/4885ADORA2B 229/4885 |
| US-20020045599-A1 | Nucleotide analog compositions | NUDT1, PNP, TYMP | ADORA2A 125/4885ADORA1 44/4885ADORA2B 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.